ePrints

Large cell neuroendocrine lung carcinoma: consensus statement from The British Thoracic Oncology Group and the Association of Pulmonary Pathologists

Lookup NU author(s): Dr Emily Shaw, Dr Fiona Black

Downloads

• Published version [.pdf]

Licence

This work is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0).

Abstract

© 2021, The Author(s).Over the past 10 years, lung cancer clinical and translational research has been characterised by exponential progress, exemplified by the introduction of molecularly targeted therapies, immunotherapy and chemo-immunotherapy combinations to stage III and IV non-small cell lung cancer. Along with squamous and small cell lung cancers, large cell neuroendocrine carcinoma (LCNEC) now represents an area of unmet need, particularly hampered by the lack of an encompassing pathological definition that can facilitate real-world and clinical trial progress. The steps we have proposed in this article represent an iterative and rational path forward towards clinical breakthroughs that can be modelled on success in other lung cancer pathologies.

Publication metadata

Author(s): Lindsay CR, Shaw EC, Moore DA, Rassl D, Jamal-Hanjani M, Steele N, Naheed S, Dick C, Taylor F, Adderley H, Black F, Summers Y, Evans M, Rice A, Fabre A, Wallace WA, Nicholson S, Haragan A, Taniere P, Nicholson AG, Laing G, Cave J, Forster MD, Blackhall F, Gosney J, Popat S, Kerr KM

Publication type: Review

Publication status: Published

Journal: British Journal of Cancer

Year: 2021

Volume: 125

Pages: 1210-1216

Print publication date: 26/10/2021

Online publication date: 06/09/2021

Acceptance date: 16/04/2021

ISSN (print): 0007-0920

ISSN (electronic): 1532-1827

Publisher: Springer Nature

URL: https://doi.org/10.1038/s41416-021-01407-9

DOI: 10.1038/s41416-021-01407-9

Share